Future directions in the treatment of HIV-HBV coinfection

HIV Therapy

Volumn 3, Issue 4, 2009, Pages 405-415

  Iser, David M ^a,b,c   Lewin, Sharon R ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Coinfection; HBV; HIV; Therapy

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; ETRAVIRINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MARAVIROC; PEGINTERFERON; POL PROTEIN; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELASTOGRAPHY; GENE SEQUENCE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER TOXICITY; MIXED INFECTION; OPEN READING FRAME; PATHOGENESIS; REVIEW; SEROCONVERSION; VIRUS DETECTION; VIRUS MUTATION; VIRUS VIRULENCE;

EID: 70349242112     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.09.19     Document Type: Review

References (101)

1. Zhou J, Dore G, Zhang F, Lim P, Chen Y: Hepatitis B and C virus coinfection in the TREAT Asia HIV Observational Database. J. Gastroenterol. Hepatol. 22, 1510-1518 (2007). (Pubitemid 47274591)
2. Alter M: Epidemiology of viral hepatitis and HIV coinfection. J. Hepatol. 44, S6-S9 (2006).
3. Weber R, Sabin CA, Friis-Moller N et al.: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 166, 1632-1641 (2006). (Pubitemid 44232373)
4. Soriano V, Puoti M, Peters M et al.: Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22, 1399-1410 (2008). •• Excellent recent review of the major issues in treating HIV-HBV coinfection.
5. Brook M, Gilson R, Wilkins E: British HIV Association guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection. HIV Med. 6, 84-95 (2005). (Pubitemid 41038587)
6. Puoti M, Torti C, Bruno R, Filice G, Carosi G: Natural history of chronic hepatitis B in coinfected patients. J. Hepatol. 44, S65-S70 (2006). • Concise review of the natural history of HIV-HBV coinfection, including areas of controversy. (Pubitemid 43053877)
7. Konopnicki D, Mocroft A, de Wit S et al.: Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19, 593-601 (2005). (Pubitemid 40543982)
8. Thio C, Seaberg E, Skolasky RJ et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicentre Cohort Study (MACS). Lancet 360, 1921-1926 (2002).
9. Blackard J, Ma G, Nelson J, Sherman K: HIV entry into hepatocytes. Presented at: HIV and Liver Disease. Jackson Hole, WY, USA, 15-16 September 2006.
10. Tuyama A, Hong F, Schecter A et al.: HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: implications for hepatic fibrosis in HIV/HCV coinfection. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008.
11. Revill P, Littlejohn M, Ayres A et al.: Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/ hepatitis B virus coinfected individuals. AIDS 21, 1701-1710 (2007). (Pubitemid 47237556)
12. Matthews G, Bartholomeusz A, Locarnini S et al.: Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20, 863-870 (2006). (Pubitemid 43731568)
13. Amini-Bavil-Olyaee S, Sheldon J, Lutz T, Trautwein C, Tacke F: Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus coinfected patient. AIDS 23, 268-272 (2009).
14. + T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J. Virol. 79, 3038-3051 (2005).
15. Brenchley J, Price D, Schacker T et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371 (2006). (Pubitemid 44924494)
16. + T-cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200, 749-759 (2005).
17. Hazenberg MD, Otto SA, van Benthem BH et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17, 1881-1888 (2003).
18. Balagopal A, Philp FH, Astemborski J et al.: Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 135, 226-233 (2008). (Pubitemid 351899010)
19. Dolganiuc A, Norkina O, Kodys K et al.: Viral and host factors induce macrophage activation and loss of Toll-like receptor tolerance in chronic HCV infection. Gastroenterology 133, 1627-1636 (2007). (Pubitemid 350029734)
20. Hoffman C, Thio C: Clinical implications of HIV and hepatitis B coinfection in Asia and Africa. Lancet Infect. Dis. 7, 402-409 (2007).
21. Tsui J, French A, Seaberg E et al.: Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin. Infect. Dis. 45, 736-740 (2007). (Pubitemid 47378888)
22. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI: Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J. Med. Virol. 81, 441-445 (2009).
23. Raimondo G, Pollicano T, Cacciola I, Squadrito G: Occult hepatitis B virus infection. J. Hepatol. 46, 160-170 (2007).
24. Chemin I, Zoulim F: Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. doi: 10.1016/j.canlet.2008.12.003 (2009) (Epub ahead of print).
25. Alberti A, Clumeck N, Collins S et al.: Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients. J. Hepatol. 42, 615-624 (2005). (Pubitemid 40501675)
26. McGovern B: The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection. Antivir. Ther. 12(Suppl. 3), H3-H13 (2007).
27. Steigbigel R, Cooper D, Kumar P et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359, 339-354 (2008).
28. Fatkenheuer G, Nelson M, Lazzarin A et al.: Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 359, 1442-1455 (2008).
29. Campbell T, Mills A, Morlat P et al.: TMC125 safety and tolerability in treatment-experienced hepatitis B or C coinfected patients in DUET-1 and DUET-2. Presented at: HEP DART: Frontiers in Drug Development for Antiretroviral Therapies. Kohala Coast, HI, USA, 9-13 December 2007.
30. Hoffman C, Charalambous S, Martin D et al.: Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin. Infect. Dis. 47, 1479-1485 (2008).
31. Carlier D, Jean-Jean O, Fouillot N, Will H, Rossignol J: Importance of the C terminus of the hepatitis B virus precore protein in secretion of HBe antigen. J. Gen. Virol. 76, 1041-1045 (1995).
32. Milich D, Liang TJ: Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 38, 1075-1086 (2003). (Pubitemid 37314815)
33. Chen M, Sallberg M, Hughes J et al.: Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. 79, 3016-3027 (2005). (Pubitemid 40270581)
34. Piroth L, Sene D, Pol S et al.: Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 21, 1323-1331 (2007). (Pubitemid 46883487)
35. Matthews GV, Avihingsanon A, Lewin SR et al.: A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 48, 1062-1069 (2008). •• First randomized trial of mono versus combination anti-HBV therapy in HIV-HBV coinfection.
36. Iloeje U, Yang H, Su J et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130, 678-686 (2006). (Pubitemid 43374518)
37. Chen C, Yang H, Su J et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73 (2006). (Pubitemid 43042691)
38. Benhamou Y: Hepatitis B in the HIVcoinfected patient. J. Acquir. Immune Defic. Syndr. 45, S57-S65 (2007).
39. Ganem D, Prince A: Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 350, 1118-1129 (2004). (Pubitemid 38298992)
40. Thio C, Locarnini S: Treatment of HIV/HBV coinfection: clinical and virological issues. AIDS Rev. 9, 40-53 (2007). •• Comprehensive review of available therapy, including a detailed discussion of drug resistance and mechanisms for cross-resistance. (Pubitemid 46730282)
41. Hadziyannis S, Tassopoulos N, Heathcote E et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131, 1743-1751 (2006). (Pubitemid 44958517)
42. Tenney D, Levine S, Rose R et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48, 3498-3507 (2004). (Pubitemid 39129351)
43. Bedossa P, Dargere, D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38, 1449-1457 (2003). (Pubitemid 37466971)
44. Chan H: Revisiting the treatment recommendations for chronic hepatitis B. Hepatology 49, 700 (2009).
45. Friedrich-Rust M, Ong M, Martens S et al.: Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134, 960-974 (2008).
46. Halfon P, Munteanu M, Poynard T: FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol. Clin. Biol. 32, 22-39 (2008).
47. Maida I, Soriano V, Castellares C et al.: Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV Clin. Trials. 7, 246-250 (2006). (Pubitemid 44963808)
48. Barreiro P, Labarga P, Martin-Carbonero L et al.: Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/ HIV-coinfected patients. Antivir. Ther. 11, 869-877 (2006). (Pubitemid 44736178)
49. Macias J, Recio E, Vispo E et al.: Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV coinfected patients. J. Hepatol. 49, 916-922 (2008).
50. Chan H, Wong G, Choi P et al.: Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (FibroScan® ) for liver fibrosis in chronic hepatitis B. J. Viral Hepat. 16, 36-44 (2009).
51. Fung J, Lai C, But D, Wong D, Cheung T, Yuen M: Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Am. J. Gastroenterol. 103, 1421-1426 (2008). (Pubitemid 351813897)
52. Kim S, Ahn S, Park J et al.: Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J. Clin. Gastroenterol. (2008) (Epub ahead of print).
53. Marcellin P, Ziol M, Bedossa P et al.: Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 29, 242-247 (2009).
54. Wong G, Wong V, Choi P et al.: Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin. Gastroenterol. Hepatol. 7, 227-233 (2009).
55. Wong G, Wong V, Choi P et al.: Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am. J. Gastroenterol. 103, 3071-3081 (2008).
56. Maida I, Garcia-Gasco P, Sotgiu G et al.: Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir. Ther. 13, 103-107 (2008). (Pubitemid 351541679)
57. Panos G, Holmes P, Valero S et al.: Cryptogenic pseudocirrhosis: a new clinical syndrome of non-cirrhotic portal hypertension (unassociated with advanced fibrosis) in patients with HIV that can be detected by transient elastography (TE) in differential diagnosis from HCV coinfection. Presented at: 4th International Workshop on HIV and Hepatitis Coinfection. Madrid, Spain 19-21 June 2008.
58. Ingiliz P, Valantin M, Duvivier C et al.: Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 monoinfected patients on antiretroviral therapy. Hepatology 49, 436-442 (2009).
59. Sorrell M, Belongia E, Costa J et al.: National institutes of health consensus development conference statement: management of hepatitis B. Ann. Intern. Med. 150, 104-110 (2009).
60. Hammer S, Eron J, Reiss P et al.: Antiretroviral treatment of adult HIV infection. 2008 recommendations of the International AIDS Society - USA panel. JAMA 300, 555-570 (2008).
61. Keeffe E, Zeuzem S, Koff R et al.: Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 5, 890-897 (2007). (Pubitemid 47127032)
62. Selabe S, Lukhwareni A, Song E, Leeuw Y, Burnett R, Mphahlele M: Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV coinfection: implications for antiretroviral therapy in HBV and HIV coinfected South African patients. J. Med. Virol. 79, 1650-1654 (2007). (Pubitemid 47479881)
63. Matthews G, Dore G: Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'. AIDS 21, 777-778 (2007). (Pubitemid 46568641)
64. Liaw Y: Results of lamivudine trials in Asia. J. Hepatol. 39, S111-S115 (2003).
65. Chang T, Lai C, Chien R et al.: Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 19, 1276-1282 (2004). (Pubitemid 39481762)
66. Westland C, Yang H, Delaney W et al.: Activity of adefovir dipivoxil against all major patterns of lamivudine-resistant HBV in patients. J. Viral Hepat. 12, 67-73 (2005). (Pubitemid 40188776)
67. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney W: Cross-resistance testing of next-generation nucleoside and nucleotide analogs against lamivudine-resistant HBV. Antivir. Ther. 10, 625-633 (2005). (Pubitemid 41224954)
68. Dore GJ, Cooper DA, Pozniak AL et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. 189, 1185-1192 (2004).
69. Marcellin P, Buti M, Krastev Z et al.: A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. Hepatology 46, 80A (2007).
70. Peters M, Andersen J, Lynch P et al.: Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 44, 1110-1116 (2006). (Pubitemid 44748362)
71. Delaney W, Borroto-Esoda K: Therapy of chronic hepatitis B: trends and developments. Curr. Opin. Pharmacol. 8, 532-540 (2008).
72. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F: The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positve and hepatitis B e antigennegative hepatitis B virus strains. Hepatology 49(4), 1158-1165 (2009).
73. Sasadeusz J, Audsley J, Mijch A et al.: The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 22, 947-955 (2008). (Pubitemid 351652245)
74. McMahon MA, Jilek BL, Brennan TP et al.: The HBV drug entecavir - effects on HIV-1 replication and resistance. N. Engl. J. Med. 356, 2614-2621 (2007).
75. Pessôa M, Gazzard B, Huang A et al.: Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 22, 1779-1787 (2008).
76. Hull M, Toy J, Montessori V et al.: Rapid rebound in hepatitis B DNA in previously undetectable hepatitis B/HIV coinfected patients switching from tenofovir to entecavir therapy. Presented at: 9th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 9-13 November 2008.
77. Marcellin P, Boyer N, Colin J et al.: Recombinant a interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 34(2 Suppl.), S106 (1993). (Pubitemid 23156103)
78. Di Martino V, Thevenot T, Colin J et al.: Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 123, 1812-1822 (2002).
79. Ingiliz P, Valantin M, Thibault V et al.: Efficacy and safety of adefovir dipivoxil plus pegylated interferon-α2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir. Ther. 13, 895-900 (2008).
80. Delaugerre C, Marcelin A, Thibault V et al.: Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob. Agents Chemother. 46, 1586-1588 (2002). (Pubitemid 34415353)
81. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M: Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133, 1445-1451 (2007). (Pubitemid 350047463)
82. Durantel S, Werle B, Durantel D et al.: Different profiles of response to adefovir dipivoxil and factors that may influence response in patients with chronic hepatitis B. Hepatology 40, 654A (2004).
83. Lai CL, Gane E, Liaw YF et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357, 2576-2588 (2007). (Pubitemid 350294224)
84. Lai C, Leung N, Teo E et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129, 528-536 (2005). (Pubitemid 41096641)
85. Standring DN, Bridges EG, Placidi L et al.: Antiviral β-l-nucleosides specific for hepatitis B virus infection. Antivir. Chem. Chemother. 12, 119-129 (2001). (Pubitemid 32924035)
86. Rockstroh JK, Bhagani S, Benhamou Y et al.: European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 9, 82-88 (2008). (Pubitemid 351228130)
87. Low E, Cox A, Atkins M, Nelson M: Telbivudine has activity against HIV-1. AIDS 23, 546-547 (2009).
88. Sung J, Lai J, Zeuzem S et al.: A randomised double-blind Phase II study of lamivudine (LAM) compared with lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. J. Hepatol. 38(Suppl. 2), 25-26 (2003).
89. Lewin S, Ribeiro R, Avihingsanon A et al.: Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology 49(4), 1113-1121 (2009)
90. Rockstroh JK, Bhagani S, Benhamou Y et al.: European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 9, 82-88 (2008). (Pubitemid 351228130)
91. French MA: Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr. HIV/AIDS Rep. 4, 16-21 (2007).
92. den Brinker M, Wit F, Wertheim-van Dillen P et al.: Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14, 2895-2902 (2000). (Pubitemid 32042753)
93. Crane M, Matthews G, Lewin S: Hepatitis virus immune restoration disease in the liver. Curr. Opin. HIV AIDS 3, 446-452 (2008).
94. Miailhes P, Trabaud MA, Pradat P et al.: Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin. Infect. Dis. 45, 624-632 (2007). (Pubitemid 47328645)
95. Drake A, Mijch A, Sasadeusz J: Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin. Infect. Dis. 39, 129-132 (2004). (Pubitemid 38879560)
96. French MA: The immunopathogenesis of mycobacterial immune restoration disease. Lancet Infect. Dis. 6, 461-462 (2006).
97. Delaney W: Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J. Antimicrob. Chemother. 59, 827-832 (2007).
98. Buchacz K, Brooks J, Tong T et al.: Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med. 7, 451-456 (2006). (Pubitemid 44269812)
99. Tenofovir, package insert. Gilead Sciences, CA, USA.
100. Liaw Y, Gane E, Leung N et al.: 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136, 486-495 (2009).
101. Iser D, Lewin S: Treatment of hepatitis B virus (HBV) in the setting of HIV-HBV co-infection. Asian Biomed. 3, 15-27 (2009).